0J7G Hutchison China Meditech Ltd

TIDMHCM

RNS Number : 6394D

Hutchmed (China) Limited

30 June 2021

Total Voting Rights

Hong Kong, Shanghai, & Florham Park, NJ : Wednesday, June 30, 2021: HUTCHMED (China) Limited (" HUTCHMED" ) (Nasdaq/AIM: HCM, HKEX: 13) hereby notifies the market that as at June 30, 2021, the issued share capital of HUTCHMED consisted of 848,515,660 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 848,515,660 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For illustrative purposes only, the 848,515,660 ordinary shares would be equivalent to 848,515,660 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 169,703,132 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM, HKEX: 13) (formerly Hutchison China MediTech) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved. For more information, please visit: www.hutch-med.com or follow us on LinkedIn .

CONTACTS

 
Investor Enquiries 
Mark Lee, Senior Vice President                              +852 2121 8200 
Annie Cheng, Vice President                                  +1 (973) 567 3786 
 
Media Enquiries 
Americas !V Brad Miles, Solebury Trout                       +1 (917) 570 7340 (Mobile) 
                                                              bmiles@troutgroup.com 
Europe !V Ben Atwell / Alex Shaw, FTI Consulting             +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 
                                                             545 055 (Mobile) 
                                                             HUTCHMED@fticonsulting.com 
Asia !V Joseph Chi Lo / Zhou Yi, Brunswick                   +852 9850 5033 (Mobile) / +852 9783 6894 (Mobile) 
                                                              HUTCHMED@brunswickgroup.com 
 
Nominated Advisor 
Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) 
 Limited                                                     +44 (20) 7886 2500 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRDZGFVRGNGMZG

(END) Dow Jones Newswires

June 30, 2021 05:01 ET (09:01 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025